Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing genetically engineered cell and genome-editing therapies for the treatment of cancer, primarily hematologic malignancies. The company operates within the biotechnology and cell and gene therapy industries, with a strategic emphasis on leveraging gene editing to enable targeted cancer treatments while protecting healthy cells.
Vor Biopharma’s core approach centers on engineering hematopoietic stem cells (HSCs) to remove specific cell-surface targets, allowing subsequent cancer therapies to selectively attack malignant cells without damaging healthy blood-forming cells. The company was founded in 2015 and went public in 2021. Its early development was closely associated with advances in genome editing and immuno-oncology, positioning the company at the intersection of cell therapy and precision oncology.
Business Operations
The company’s operations are primarily organized around the research and development of gene-edited HSC therapies. Its lead clinical programs have focused on deleting the CD33 antigen from donor-derived HSCs to enable the use of CD33-targeted therapies for acute myeloid leukemia (AML) without causing prolonged bone marrow toxicity. Revenue generation to date has been limited, as the company remains in the clinical development stage and does not have approved commercial products.
Vor Biopharma’s activities are concentrated in the United States, with laboratory, clinical development, and corporate functions integrated around its R&D platform. The company controls proprietary gene-editing technologies and relies on a combination of internal development and third-party manufacturing and clinical research partners. As of publicly available disclosures, operations have been streamlined in response to clinical and strategic reassessments, and certain development programs have been paused. Data inconclusive based on available public sources regarding the timing and scope of future program restarts.
Strategic Position & Investments
Strategically, Vor Biopharma has aimed to establish a differentiated position in oncology by combining genome editing with cell therapy to create what it describes as a “shielded” therapeutic platform. Growth initiatives have historically centered on advancing clinical trials in AML and expanding the applicability of its platform to other hematologic cancers.
The company has made significant investments in its proprietary HSC engineering platform rather than pursuing a broad acquisition strategy. Its portfolio has consisted primarily of internally developed candidates rather than acquired assets. Public disclosures indicate that management has undertaken restructuring actions to preserve capital and evaluate strategic alternatives following mixed clinical outcomes. Data inconclusive based on available public sources regarding new acquisitions or external investments beyond its core platform.
Geographic Footprint
Vor Biopharma is headquartered in the United States, with its principal executive offices and research operations located in Cambridge, Massachusetts, a major global biotechnology hub. Its clinical activities have been conducted primarily in North America, supported by collaborations with U.S.-based clinical research centers.
While the company does not maintain a broad international operational footprint, its therapies are intended for global oncology markets, and its regulatory and clinical strategies have been designed with potential future expansion into Europe and other major healthcare regions. International influence remains limited to clinical planning and investor outreach rather than direct overseas operations.
Leadership & Governance
Vor Biopharma was co-founded by leaders in the cell therapy and genome-editing fields, reflecting a governance philosophy centered on scientific innovation and translational medicine. The company’s leadership has emphasized disciplined capital allocation, clinical rigor, and long-term platform value, particularly in response to evolving clinical data.
Key executives and leaders include:
- Robert Ang, PhD – President and Chief Executive Officer
- Derrick Rossi, PhD – Co-Founder
Public disclosures confirm Robert Ang as the company’s current CEO. Information regarding additional current C-suite executives is inconsistent across available public sources; therefore, data inconclusive based on available public sources for other executive roles beyond those listed.